Cyient DLM Ltd. share price target

High backlog visibility trumps near-term operational headwinds : Cyient DLM (CDLM) is an integrated Electronics Manufacturing Services (EMS) provider and Design-Led Manufacturing (DLM) provider. As a subsidiary of Cyient Limited, CDLM specializes in design-led manufacturing, printed circuit board assemblies (PCBA), box builds and mission-critical systems. It serves highly regulated sectors with a FY26 diversified revenue mix: aerospace &...

Cyient DLM (CYIENTDL)’s 2QFY27 consol. revenue grew 27% YoY to INR3.9b, largely aided by a 61%/2.5x YoY growth in the aerospace/ MedTech segments. EBITDA margin contracted 130bp YoY to 8.7%, because of gross margin compression due to the expensing of product development costs.

segments : CDLM is venturing into new, emerging and high-growth segments including Semiconductor equipment, AI Data centers and Robotics during FY27E. We believe the semiconductor segment particularly has multi-year growth visibility with Government approving the next phase of the Semicon India Program (ISM 2.0), with an outlay of ~1,27,500 crore to accelerate the development of a resilient semiconductor and electronics ecosystem in India. The recently concluded Semicon India 2026 saw significant investments from multinational giants...

Cyient DLM (CYIENTDL IN) Visit Update Focus on B2S & new-age electronics to drive growth HOLD

Cyient DLM Ltd (CYIENTDL) is an emerging design-led electronics platform serving Aerospace & Defense, Industrial, MedTech, and Automotive end-markets (with AI data centers and robotics segments expected from FY27 onwards), positioned at the intersection of several technology and manufacturing megatrends.

Q1FY27 performance: CDLM reported strong set of results as business rebounded from negative growth trajectory to revenue being recorded at 373.8 crore, up 34.3% YoY (+1.3% QoQ) backed by strong growth in aerospace (~41% YoY) and industrials verticals (~87% YoY). EBITDA margins came in at 10.5% up 147 bps YoY (down 120 bps QoQ), reflecting benefits of operating leverage, better revenue mix and cost management. PAT reported at 16.3 crore which grew by ~119% YoY (28% QoQ). Order book remained healthy at ~2598 crore with order inflows of ~552 crore in Q1 and book-to-bill ratio of 1.5x. Managements targets expanding...

We expect Cyient DLM to deliver a Revenue/EBITDA/PAT CAGR of 30.5%/45.6%/51.2% over FY26–FY28, driven by favourable industry tailwinds, healthy order execution, and strong support from the Cyient parent ecosystem.

Cyient DLM’s (CYIENTDL) 1QFY27 consolidated revenue/EBITDA grew 34%/56% YoY to INR3.7b/INR392m, largely aided by 41%/95% YoY growth in aerospace/industrial segments.

We expect Cyient DLM to report revenue of INR 3,552 million in Q1FY27, reflecting 28% YoY growth but a 4% QoQ decline, primarily due to seasonal weakness in the first quarter.

Cyient DLM is expected to see a strong recovery in the coming quarters, driven by execution of its healthy order backlog, ramp-up of recently won orders, and a higher contribution from the box-build segment.

39%/28%/21% to the revenue in Q4FY26. EBITDA declined by 25.0% YoY to Rs 431mn (PLe: Rs 407mn). EBITDA margins contracted by ~170bps to 11.7% (PLe: 10.0%). PBT declined by 24.0% YoY at Rs 317mn (PLe: Rs 296mn). PAT declined by 23.0% YoY to Rs 239mn (PLe: Rs 222mn). The company is having an orderbook of Rs 24bn in Q4FY26 vs...

Cyient DLM’s (CYIENTDL) 4QFY26 consolidated revenue/EBITDA declined ~14%/25% YoY to INR3.7b/INR431m, owing to a higher base of BEL orders and geopolitical disruptions in West Asia.

Cyient DLM is expected to see a gradual recovery in performance over the coming quarters, supported by execution of its healthy order backlog, ramp-up of recently won industrial and medical programs, and an increasing contribution from box-build and B2S revenues.

Cyient DLM’s (CYIENTDL) 3QFY26 consolidated revenue/EBITDA declined ~32%/19% YoY to INR3b/INR291m. This was led by a higher base of BEL orders and a 39% YoY decline in the Med Tech segment.

The company is witnessing a temporary softness led by the completion of large defense orders and muted PCBA volumes, however the growth trajectory is expected to revive meaningfully from Q4 FY26 onward.

Cyient DLM’s (CYIENTDL) 2QFY26 consolidated revenue/EBITDA declined ~20%/1% YoY to INR3.1b/INR312m. However, EBITDA margins expanded 190bp YoY to 10% (est. 9.7%), led by a better business mix (higher Aerospace mix of 37%).

Cyient DLM’s Q1FY26 performance was a sharp miss to our estimates, led by a decline in defense segment, driven by completion of a order from a large customer last year.

we resume our coverage with a HOLD rating on the stock.

We cut our earnings estimates by 2.5% for both FY26/FY27E mainly with correction in OI. However, CYIENTDL is confident to report 10%+ EBITDA margin in FY26 with improvement in revenue through gradual pickup in orderbook. We have revised TP to Rs540 (Rs546 earlier), based on 30x FY27E earnings and maintain our recommendation to Accumulate'. CYIENTDL defense segment got impacted due to completion of contract from domestic client (BEL), with the order book remained flat YoY to Rs 21bn. However, the company remains positive on maintaining book to bill ratio to >1x in FY26. In...

the operating performance of the company at the fag end of the quarter. The impact was visible across verticals and geographies (ex-Europe). The management indicated that the softness should continue in the subsequent quarters, however the degree of impact would be lesser than that of Q4. We believe the combination of CYL's structural challenges along with the...